A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis

Current Opinion in Chemical Biology

Volumn 6, Issue 4, 2002, Pages 486-492

  Adams, Jerry ^a   Huang, Pearl ^a   Patrick, Denis ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANGIOGENESIS INHIBITOR; AXITINIB; BSF 466895; CELL ENZYME; CHIR 200131; FIBROBLAST GROWTH FACTOR RECEPTOR; KRN 633; META TYROSINE; PD 166285; PD 173074; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SU 6688; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; MOLECULAR BIOLOGY; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036679979     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(02)00357-5     Document Type: Review

References (44)

1. VEGF antagonists
2. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases
3. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors
4. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
5. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy
6. New paradigms for the treatment of cancer: The role of anti- angiogenesis agents
7. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
8. Structure activity relationships for a novel series of pyrrolo[2,3-d]pyrimidine tie-2 Inhibitors
9. Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase
10. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
11. Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
12. Oncogenic kinase signalling
13. Autoinhibitory mechanisms in receptor tyrosine kinases
14. The conformational plasticity of protein kinases
15. Specificity and mechanism of action of some commonly used protein kinase inhibitors
16. The development and therapeutic potential of protein kinase inhibitors
17. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinase
18. The structure-based design of ATP-site directed protein kinase inhibitors
19. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
20. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution
21. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors
22. P38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines
23. Unnatural ligands for engineered proteins: New tools for chemical genetics
24. The protein kinases of Caenorhabditis elegans: A model for signal transduction in multicellular organisms
25. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
26. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
27. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
28. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response
29. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
30. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
31. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
32. Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis, vessel density and microvascular architecture in murine renal cell carcinoma
33. Characterization of potent tyrosine kinase inhibitors that modulate angiogenesis and proliferation of selected cancer cell lines
34. In vivo preclinical evaluation of tyrosine kinase inhibitors with potent effects on tumor angiogenesis, growth and metastasis
35. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
36. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
37. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
38. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
39. In vivo anti-tumor and mechanism of action studies of SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors
40. Preliminary pharmacokinetic (PK) characteristics of an oral vascular endothelial growth factor receptor-2 (VEFGR-2) tyrosine kinase inhibitor (TKI), Cp-547,632 in patients (Pts) with advanced solid tumors
41. CEP-7055: an orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor efficacy against human tumor xenograft growth
42. Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736
43. Synthesis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors
44. The protein tyrosine kinase family of the human genome